Status:
COMPLETED
Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI)
Lead Sponsor:
Alexandria University
Conditions:
Female Infertility
Eligibility:
FEMALE
20+ years
Phase:
PHASE4
Brief Summary
Despite the use of various treatment strategies, poor response to ovarian stimulation remains a major clinical challenge with lower chance to obtain sufficient number of oocytes and thus less likely t...
Eligibility Criteria
Inclusion
- Infertile women aged 20-45 years.
- AFC \<5.
- AMH level \<1.2 ng/ml.
- Have two normal ovaries and normal uterine cavity.
Exclusion
- Body mass index (BMI) \>30 kg/m2.
- Follicle Stimulating Hormone (FSH) \> 15 IU/L.
- History of abnormal karyotype in one or both partners.
- Endocrine, metabolic or autoimmune disorders, such as diabetes, thyroid disorder, and polycystic ovary syndrome (PCOS).
- Women with a known medical disease (e.g. severe hypertension or hepatic disease).
- Endometriosis.
- Previous ovarian surgery.
- Current or history of malignancies, chemotherapy or radiotherapy.
- Severe male actor (total motile sperm count \<1×106 or normal morphology \<1%)
Key Trial Info
Start Date :
January 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 13 2022
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT05281341
Start Date
January 13 2020
End Date
February 13 2022
Last Update
August 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
faculty of medicine, Alexandria University
Alexandria, Egypt, 21131